Every night, the online Belgian patent register ('eRegister') receives an update with public data that were entered or generated the preceding day on the Benelux Patent Platform, the computer application with which the Belgian Intellectual Property Office handles the registration, treatment and publication processes for patents and supplementary protection certificates.
Currently, some updates are spread over consecutive nights due to the large, weekly volume of data concerning European patents designating Belgium.
For a European patent it is possible that data about the inventor(s) are missing from the online Belgian patent register. They can be found via the link to the European patent register pending an update of the Belgian patent register.
For European patents with Unitary Effect, the authentic source of information is the European Patent Register : please refer to it.

Patent details

2022C513 Product name: Lonapegsomatropin

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic information

Application number:
2022C/513
Type:
Certificate
SPC type:
Medical
Basic patent number:
192148641
Status:
Open & Published
Publication number:
2022C513
1rst applicant's nationality:
Procedural language:
French

Marketing authorization

Marketing authorization number:
EU/1/21/1607
Marketing authorization type:
National/EU
Designates country:
No
Marketing authorization date:
17/01/2022
Marketing authorization status:
Accepted
Marketing authorization country:
Belgium (BE)

Dates

Filing date:
29/04/2022
First marketing authorization date:
17/01/2022
Grant date:
Activation date:
BE Publication date:
02/05/2022
Lapsed date:
Expiration date (if granted and all annual fees paid):
Basic SPC Expiration (if granted and all annual fees paid):
17/01/2037
SPC/SPC Extension Expiration (if granted and all annual fees paid):
17/01/2037
Rejection date:
Withdrawal date:

Applicant

Name:
ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S
Legal Form:
SA : société anonyme
From:
02/05/2022
Address:
Tuborg Boulevard 12, 2900, Hellerup, Denmark (DK)
To:

Agent

Name:
CALYSTA NV
Legal Form:
From:
30/04/2022
Address:
5A Lambroekstraat, 1831, DIEGEM, Brussels, Belgium (BE)
To:

Publication

Bulletin

Bulletin heading:
SPC
Journal edition number:
2022/09
Publication date:
20/05/2022
Description:
Contains data concerning applications for- or granted Supplementary Protection Certificates

Annual fee

Annual fee(s) Due Date:
30/11/2035
Annual fee number:
21
Annual fee amount:
650 Euro
Expected payer:
Last annual fee payment date:
Last annual fee paid number:
Payer:
Filing date Document type Publication Type Document Description Number of pages File Type
29/04/2022 Power Of Attorney Power of attorney 1 PDF /7/5/9/1/2/0722221957/docs/2022c513_0_powerofattorney_20220430_084629196.pdf
29/04/2022 General Document Other 4 PDF /7/5/9/1/2/0722221957/docs/2022c513_1_generaldocument_20220430_084628967.pdf
29/04/2022 Abstract Product Characteristics Abstract of the characteristics of the product 89 PDF /7/5/9/1/2/0722221957/docs/2022c513_2_abstractproductcharacteristics_20220430_084629563.pdf
29/04/2022 General Document Other 9 PDF /7/5/9/1/2/0722221957/docs/2022c513_3_generaldocument_20220430_084629354.pdf
29/04/2022 MA Official Publication Official Publication of 1st Marketing Authorization 10 PDF /7/5/9/1/2/0722221957/docs/2022c513_4_maofficialpublication_20220430_084630056.pdf
29/04/2022 General Document Other 36 PDF /7/5/9/1/2/0722221957/docs/2022c513_5_generaldocument_20220430_084632389.pdf
29/04/2022 Application Form 4 PDF /7/5/9/1/2/0722221957/docs/2022c513_6_applicationform_20220430_084633581.pdf
02/05/2022 Publication I1 1 PDF /7/5/9/1/2/0722221957/docs/2022c513_7_i1document_20220502_085115252.pdf
02/05/2022 Outgoing Correspondence 2 PDF /7/5/9/1/2/0722221957/docs/2022c513_8_outgoingcorrespondence_20220503_092442825.pdf